title: Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer.
abstract: OBJECTIVE
  We performed a clinical trial to determine whether postoperative adjuvant chemotherapy with two drugs versus one drug could prolong survival.
  
  
  METHODS
  From 1985 to 1996, 85 patients with completely resected locally advanced gastric cancer were enrolled. The subjects were randomized into two treatment groups, as follows: mitomycin (MMC) 10 to 20 mg/m2 intravenously (i.v.) on day 1 every 6 weeks plus ftorafur (FT) 500 mg/m2/d for 36 consecutive days; or MMC alone, 10 to 20 mg/m2 i.v. every 6 weeks. All courses were repeated four times.
  
  
  RESULTS
  After a median follow-up duration of 62 months, the overall 5-year survival rates were 67% for the MMC-FT group versus 44% for the MMC group (P = .04). Subgroup analysis to compare survival curves using the method of Mantel-Cox showed survival rates significantly in favor of the MMC-FT group in the subsets of patients with node-negative disease (P = .01) and those whose disease was stage IB or II (P = .008).
  
  
  CONCLUSIONS
  Significantly better survival results were observed for MMC-FT versus MMC alone. Subset analysis suggest a strong benefit in patients with node-negative and early-stage resected gastric cancer.
authors.affiliation: University of Barcelona, Hospital Clinic, Villarroel, Spain.
authors.forename: J J
authors.initials: JJ
authors.lastname: Grau
authors.forename: J
authors.initials: J
authors.lastname: Estapé
authors.forename: J
authors.initials: J
authors.lastname: Fuster
authors.forename: X
authors.initials: X
authors.lastname: Filella
authors.forename: J
authors.initials: J
authors.lastname: Visa
authors.forename: J
authors.initials: J
authors.lastname: Terés
authors.forename: G
authors.initials: G
authors.lastname: Soler
authors.forename: S
authors.initials: S
authors.lastname: Albiol
authors.forename: J C
authors.initials: JC
authors.lastname: García-Valdecasas
authors.forename: L
authors.initials: L
authors.lastname: Grande
authors.forename: J
authors.initials: J
authors.lastname: Bombí
authors.forename: J
authors.initials: J
authors.lastname: Bordas
authors.forename: F
authors.initials: F
authors.lastname: Alcobendas
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage / Q000627:therapeutic use*; D013156:Splenectomy; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D016019:Survival Analysis; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D005641:Tegafur